Cannabis use among cancer survivors before and during the COVID-19 pandemic, 2019-2021.
JNCI Cancer Spectr
; 7(3)2023 05 02.
Article
in English
| MEDLINE | ID: covidwho-2303133
ABSTRACT
We estimated the prevalence of past 30-day cannabis use, evaluated reasons for use, and identified individual-level factors associated with cannabis use among cancer survivors before (2019) and during (2020 and 2021) the COVID-19 pandemic. Cancer survivors, aged 18 years and older, were identified from the 2019 (n = 8185), 2020 (n = 11â084), and 2021 (n = 12â248) Behavioral Risk Factor Surveillance System. Prevalence of past 30-day cannabis use among survivors held steady through the pandemic (8.7%, 7.4%, and 8.4% in 2019, 2020 and 2021, respectively). Of those who used cannabis, 48.7% used it for medical reasons in 2019, 54.5% in 2020, and 43.5% in 2021. Survivors were more likely to report past 30-day cannabis use if they were younger, male, current or former tobacco smokers, and binge alcohol consumers and if they experienced poor mental health in the past 30-days. Our study identified subpopulations of cancer survivors that need to be targeted for evidence-informed discussions about cannabis use.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cannabis
/
Cancer Survivors
/
COVID-19
/
Neoplasms
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Qualitative research
Limits:
Humans
/
Male
Language:
English
Year:
2023
Document Type:
Article
Affiliation country:
Jncics
Similar
MEDLINE
...
LILACS
LIS